APOL1 Long-Term Kidney Transplantation Outcomes Network (APOLLO)

G. Guerra,¹ E. Poggio,² M. Ortigosa-Goggins,¹ M. Doshi,³ B. Freedman,⁴ D. Reboussin,⁴ P. Kimmel,⁵ APOLLO Investigators.

¹Miami Transplant Institute, Miami, FL
²Cleveland Clinic, Cleveland, OH
³University of Michigan, Ann Arbor, MI
⁴Wake Forest School of Medicine, Winston-Salem, NC
⁵NIDDK, Bethesda, MD.

Meeting: 2018 American Transplant Congress

Abstract number: D141

Keywords: Allocation, Donation, Outcome

Session Information

Session Name: Poster Session D: Kidney Donor Selection / Management Issues

Session Type: Poster Session

Date: Tuesday, June 5, 2018

Session Time: 6:00pm-7:00pm

Presentation Time: 6:00pm-7:00pm

Location: Hall 4EF

Two renal-risk variants in the apolipoprotein L1 gene (APOL1) are powerfully associated with a spectrum of non-diabetic chronic kidney diseases in populations with recent African ancestry. Retrospective studies demonstrate that presence of two APOL1 renal-risk variants (defining risk genotypes) in deceased donor kidneys associate with shorter renal allograft survival after transplantation, without effect of recipient genotypes. Case reports also suggest the potential for kidneys transplanted from living donors with APOL1 risk genotypes to develop post-transplant focal segmental glomerulosclerosis with early graft failure; some living donors may be at increased risk for developing subsequent end-stage kidney disease.

The "APOL1 Long-term Kidney Transplantation Outcomes Network" (APOLLO) is an NIH-supported Consortium established to investigate effects of variation in APOL1 on outcomes in living and deceased donor kidney transplantation. APOLLO will work closely with the United Network for Organ Sharing (UNOS), Association of Organ Procurement Organizations (AOPO), and the kidney transplant community to prospectively follow outcomes of living and deceased donor kidneys transplanted from individuals with recent African ancestry. Deceased and live donors along with their intended recipients will be enrolled prospectively, genotyped for APOL1 renal -risk variants and ancestry informative markers. Effects of donor and recipient APOL1 genotypes on outcomes of kidney transplantation along with post-donation health status of living donors will be assessed. The Consortium consists of a Scientific Data and Research Center (Coordinating Center) and 13 Clinical Centers that will align with all U.S. kidney transplantation programs with the aim of full participation throughout the country. The protocol is being developed and enrollment is expected to begin by summer of 2018.

Results in APOLLO have the potential to improve allocation of deceased donor kidneys, better match donor kidneys with recipients to increase allograft survival, reduce rates of organ discard and increase numbers of transplanted kidneys. APOLLO may better inform the safety of kidney donation in living donors who possess recent African ancestry.

CITATION INFORMATION: Guerra G., Poggio E., Ortigosa-Goggins M., Doshi M., Freedman B., Reboussin D., Kimmel P., APOLLO Investigators APOL1 Long-Term Kidney Transplantation Outcomes Network (APOLLO) Am J Transplant. 2017;17 (suppl 3).

To cite this abstract in AMA style:

Guerra G, Poggio E, Ortigosa-Goggins M, Doshi M, Freedman B, Reboussin D, Kimmel P, Investigators APOLLO. APOL1 Long-Term Kidney Transplantation Outcomes Network (APOLLO) [abstract]. https://atcmeetingabstracts.com/abstract/apol1-long-term-kidney-transplantation-outcomes-network-apollo/. Accessed May 11, 2025.

« Back to 2018 American Transplant Congress